Mylan/Gilead, AbbVie/MPP boost access to HIV medicines

Access to Gilead Sciences's next-generation HIV medicines and pediatric formulations of AbbVie's biggest-selling antiviral therapy will increase in developing countries under new agreements with commercial and nonprofit partners, Mylan and the Medicines Patent Pool (MPP).